Diabetes self-assessment score and the development of diabetes
A 10-year prospective study

Gyuri Kim, MD, PhD, Yong-ho Lee, MD, PhD, Byung-Wan Lee, MD, PhD, Eun Seok Kang, MD, PhD, In-Kyu Lee, MD, PhD, Bong-Soo Cha, MD, PhD, Dae Jung Kim, MD

Abstract
To verify that the Korean Diabetes Score (KDS), a self-assessment, predicts the risk of diabetes in various comprehensive risk models, and to investigate factors that enhance its predictive ability in a large cohort. We analyzed 8735 adults without diabetes in the Korean Genome and Epidemiology Study, an ongoing large community-based 10-year cohort study. Incident diabetes was defined as fasting blood glucose ≥126 mg/dL or postload 2-hour glucose ≥200 mg/dL by 75 g oral glucose tolerance test conducted biennially, or currently taking medication for diabetes. Hazard ratios (HRs) using Cox regression were calculated for relative risk of developing diabetes as associated with the KDS, and performance of risk models was assessed by area under the receiver-operating characteristic curve (AUC). Of 8735 participants, 1497 (17.1%) developed diabetes over 10 years. The prevalence of incident diabetes was 10.3% in people with a KDS <5 and was 21.8% in those with KDS ≥5 (P<.001). Increasing KDS was significantly associated with developing diabetes (adjusted HR: 1.13; 95% confidence interval: 1.09, 1.18). The comprehensive prediction model with KDS added to fasting glucose, glycated hemoglobin, postload 2-hour glucose, and triglyceride showed a markedly higher AUC (0.782) compared to KDS alone (0.641). A low insulinogenic index (IGI) level, but not insulin resistance, was a significant determinant of developing diabetes in subjects who had baseline KDS <5. We confirmed that KDS as a 10-year risk model to predict diabetes becomes more potent when added to relevant laboratory parameters. Beta-cell function as assessed by IGI should be taken into account when predicting diabetes using the KDS.

Abbreviations: AUC = area under the receiver-operating characteristic curve, BMI = body mass index, CI = confidence interval, DM = diabetes mellitus, HbA1c = glycated hemoglobin, HDL = high-density lipoprotein, HOMA-IR = homeostasis model assessment of insulin resistance, HR = hazard ratio, IGI = insulinogenic index, KDS = Korean Diabetes Score, KoGES = Korean Genome and Epidemiology Study, OGTT = oral glucose tolerance test, ROC = receiver-operating characteristic, SBP = systolic blood pressure.

Keywords: diabetes, prediction, prospective, risk factor

1. Introduction
Type 2 diabetes mellitus (DM), a major health problem, is increasing worldwide. The estimated 382 million people with diabetes in 2013 is predicted to rise to 592 million by 2035 globally. In the United States, the estimated prevalence of diabetes is 12% to 14% among adults in the overall population. The prevalence of diabetes in the Western Pacific region is also increasing rapidly and is expected to exceed 202 million by 2035, which is attributable to rapid urbanization and changes in lifestyle. In the United States, the estimated prevalence of diabetes is 12% to 14% among adults in the overall population.
lifestyle and epigenetics.[14,53] Diabetes has been associated with chronic metabolic conditions such as obesity and metabolic syndrome, as well as related macrovascular and microvascular complications.[93] Consequently, these complications and mortality represent an increasing burden on socioeconomic and public healthcare systems.[17,81] Therefore, a focus on prevention and early detection of diabetes is urgently needed.

A number of diabetes risk scoring models have been developed.[95–122] Because these risk scoring models are designed primarily for Western people, and because the pathophysiology of Type 2 DM is different in Asians, these methods may not be suitable.[113] Moreover, because more than 60% of people with diabetes live in Asian countries and have a great impact on global epidemics,[141] it is critical to focus on the development of diabetes in Asians. Therefore, the KDS was developed to assess the risk of diabetes in Koreans without requiring any blood tests.[115] However, it has not been fully validated to predict diabetes in a large prospective cohort. Therefore, we aimed to investigate and validate not only the KDS but also a comprehensive risk model combining laboratory variables as useful tools for predicting diabetes in a 10-year longitudinal cohort of 10,030 people in Korea. In addition, we also sought to identify risk factors for diabetes in low-risk people with low KDS scores at baseline who ultimately develop diabetes, to predict incident diabetes.

2. Methods

2.1. Study population

The Korean Genome and Epidemiology Study (KoGES) is an ongoing prospective study that enrolled 10,030 participants aged 40 to 69 years who live in urban Ansan or rural Ansong communities in the Republic of Korea. Begun in 2001, for baseline recruitment, eligible participants were recruited as volunteers through on-site invitation, telephone calls, letters, media campaign, or community conferences.[16] The KoGES includes results of biennial self-reported questionnaires regarding medical history, family history, smoking and alcohol consumption, and exercise status and health examinations by trained staff at the survey sites, including national medical schools, hospitals, and health institutions. Exclusion criteria in this study are: current steroid users (N = 15), individuals with previously diagnosed diabetes or any oral hypoglycemic agents or insulin (N = 682), missing results from a 75g oral glucose tolerance test (OGTT) (N = 45), and participants with fasting glucose concentration ≥126 mg/dL or a postload 2-hour glucose concentration by a 75-g OGTT ≥200 mg/dL (N = 55) (Supplementary Fig. 1, http://links.lww.com/MD/B726). Ultimately, a total of 8735 individuals were analyzed in the present study. Among 8735 participants at baseline, 5549 individuals were successfully followed up to Year 10. This study was approved by the Korean Center for Disease Control and Prevention and the Institutional Review Board of the Severance Hospital (IRB No: 4-2014-0508).

2.2. Data and measurements

Baseline measurements of height, weight, and waist circumference were obtained. Body mass index (BMI) was calculated as kg/m² from measured height and weight. Obesity was defined as BMI ≥25 kg/m² by criteria of the Asian and Pacific regions.[17–19] Blood pressure was measured 3 times in the morning, after at least 10 minutes in the sitting position. Hypertension was diagnosed in subjects who were taking hypertension medication or a measured blood pressure ≥140/90 mm Hg. Smoking and alcohol consumption were categorized into 3 categories as never, past smoker, or current smoker, and none, <1, 1–4.9, or ≥5 drinks per day, respectively. Exercise status was stratified into 3 groups according to frequency of exercise (none, 1–3 times, or ≥4 times weekly). After a 12-hour fast, plasma total cholesterol, triglyceride, and high-density lipoprotein (HDL) cholesterol were determined using a 747 chemistry analyzer (Hitachi Ltd, Tokyo, Japan). Low-density lipoprotein cholesterol level was calculated by the Friedewald equation: total cholesterol-HDL cholesterol-triglycerides/5. In a 75-g OGTT, plasma glucose and insulin levels at 0, 60, and 120 min were measured by using the hexokinase method and radioimmunoassay (LINCO kit, St Charles, MO), respectively. Glycated hemoglobin (HbA1c) level was measured by high-performance liquid chromatography (Variant II; Bio-Rad Laboratories, Hercules, CA). In this study, the diagnostic criteria for incident diabetes was current oral hypoglycemic agents or insulin, a fasting glucose level ≥126 mg/dL, or a postload 2-hour glucose level ≥200 mg/dL by biannually conducted 75-g OGTT, based on the American Diabetes Association criteria.[20] Homeostasis model assessment of insulin resistance (HOMA-IR) and 60 minutes insulinogenic index (IGI) were calculated using the following indices: fasting plasma insulin (µIU/mL) × fasting plasma glucose (mg/dL)/405 and (postload 60-minute insulin – fasting insulin [µIU/mL])/(postload 60-minute glucose – fasting glucose [mmol/L]), respectively.[21,22] Criteria for diagnosis of metabolic syndrome according to the revised National Cholesterol Education Program definition were 3 or more of the following: waist circumference >90 cm in men or >80 cm in women; serum triglycerides ≥150 mg/dL or medication use; HDL cholesterol level <40 mg/dL in men or <50 mg/dL in women; blood pressure ≥130/85 mm Hg or hypertension medication use; or serum fasting glucose ≥100 mg/dL or diabetes medication use.[23,24]

2.3. Korean diabetes score

Points for the Korean Diabetes Score (KDS) were assessed by following criteria as previously described[15,21]: age: <35 years old was determined as 0, 35–44 years old as 2, and ≥45 years old as 3; waist circumference: percentiles 51–74 as 2, and >75 as 3; alcohol consumption per day: <1 drink was determined as 0, 1–4.9 drinks as 1, and ≥5 drinks as 2; and family history of diabetes, history of hypertension, and smoking status were determined as 0 or 1. KDS score ≥5 was regarded as a cut point for being at high risk for diabetes.[13]

2.4. Statistical analyses

Data are presented as means ± standard deviations or frequencies with percentages. Differences were analyzed using Chi-square tests for categorical variables and Student t tests or 1-way analysis of variance followed by the Tukey honestly significant difference post hoc test for multiple comparisons, for continuous variables. Cox proportional hazard analysis was performed to estimate whether the KDS was associated with incident diabetes and to determine the independent relationship of the variables for developing diabetes. Cumulative event rates for developing diabetes were accessed by Kaplan–Meier survival curves, and equality was compared with the log-rank test. To compare the combined effect of using the KDS and various parameters for
predicting incident diabetes, we evaluated receiver-operating characteristic (ROC) curves and the areas under the receiver-operating characteristic curves (AUCs) as a discrimination index. For the comparison of ROC curves between various models, DeLong methods were used. \(^{[12]}\) A \( P < .05 \) was considered statistically significant. Statistical analyses were performed using PASW Statistics version 20.0 for Windows (SPSS Inc., Chicago, IL) and MedCalc software for Windows (Version 13.1, Ostend, Belgium).

3. Results

3.1. Clinical and laboratory characteristics of participants at baseline

The mean age of participants was 51.7 ± 8.8 years; 53.3% were women, and the mean BMI was 24.5 ± 3.0 kg/m\(^2\). Of these 8735 participants, 1513 (17.3%) progressed to diabetes during the 10-year follow-up period. There were 3388 (38.8%) participants with a KDS < 5 and 3547 (61.2%) had a KDS ≥ 5 at baseline.

Participants' baseline clinical and laboratory characteristics according to presence of incident diabetes during the follow-up period and a cut point of KDS of 5 are shown in Table 1. Individuals with incident diabetes or a KDS ≥ 5 tended to be older, more likely to be men, more obese, more hypertensive, to have more family history of diabetes, more likely to smoke, and to have metabolically unhealthy parameters compared to those with nondiabetes or KDS < 5. When compared to individuals with a KDS ≥ 5 who ultimately did not develop diabetes, those with KDS < 5, but ultimately develop diabetes, showed significant younger ages, lower BMI, less hypertensive, less likely to smoke or drink, less likely to have metabolic syndrome, but with markedly higher levels of HbA1c and fasting glucose. Moreover, despite markedly lower HOMA-IR index (1.40 vs 1.64; \( P < .001 \)), individuals with KDS < 5 and incident diabetes presented with significant lower levels of fasting insulin (6.6 vs 8.0 \( \mu \text{IU/mL}; P < .001 \)) and IGI (7.0 vs 15.8; \( P < .001 \)) relative to individuals with KDS ≥ 5 but who ultimately did not develop diabetes. In particular, levels of fasting insulin and IGI in subjects with KDS < 5 but who ultimately developed diabetes were the lowest among 4 groups in Table 1.

3.2. Relationship between KDS and incident diabetes

Figure 1 illustrates that the proportion of incident diabetes over 10 years gradually increased as KDS scores rose. The mean prevalence of incident diabetes is 10.3% in participants with a KDS < 5 and is 21.8% in those with KDS ≥ 5 (\( P < .001 \)). Based on the KDS cutoff point of 5, participants with KDS ≥ 5 had a markedly increased cumulative incidence of diabetes compared to those with KDS < 5 (Fig. 2; \( P < .001 \)) by log-rank test.

To test the independent association between KDS score and incident diabetes over 10 years, we performed Cox proportional hazards analysis and variables such as age, smoking and alcohol consumption, and family history of diabetes that were composed of KDS, were excluded in covariates in the analysis (Table 2). A 1-point increase in KDS score presented a significantly elevated adjusted hazard ratio (HR) for incident diabetes after adjusting for sex, exercise status, levels of HbA1c, fasting glucose, postload 2-hour glucose, total cholesterol, triglyceride, HDL cholesterol, IGI, and HOMA-IR index (HR:1.13; 95% confidence interval [CI]:1.09–1.18; \( P < .001 \)). In addition, male sex, levels of HbA1c, fasting glucose, postload 2-hour glucose, triglyceride, and IGI were significant determinants of incident diabetes.

### Table 1

| Baseline characteristics of the subjects according to KDS score and the development of diabetes (\( N = 8735 \)). |

|                     | Nondiabetes (\( N = 7222 \)) | Incident diabetes (\( N = 1513 \)) | \( P \) |
|---------------------|-------------------------------|-----------------------------------|------|
| Age, y              | 48.7 ± 8.4                    | 50.3 ± 8.6                        | .001 |
| Female, n (%)       | 1966 (64.6)                   | 160 (45.8)                        | .001 |
| Waist circumference, cm | 174.6 ± 5.6               | 192.5 ± 19.2                      | .001 |
| BMI, kg/m\(^2\)     | 22.5 ± 2.3                    | 21.8 ± 2.8                        | .001 |
| Obesity, n (%)      | 301 (9.9)                     | 124.0 ± 17.9                      | .001 |
| Hypertension, n (%) | 11272 (50.1)                  | 2457/526/1200 (58.7/12.6/28.7)    | .244 |
| SBP, mm Hg          | 1203 ± 14.1                   | 118.0 ± 18.7                      | .001 |
| Family history of diabetes, n (%) | 215 (7.1) | 247/526/526 (14.6/16.3/19.1) | .001 |
| Smoking, never/past/current, n (%) | 1983/95/58 (64.6/16.3/19.1) | 2475/7222 (58.7/12.6/28.7) | .001 |
| Alcohol, ≥1/4/9/35 drinks/day, n (%) | 2757/257/791 (91.3/5.9/5.2) | 3132/280/1050 (74.9/19.1/6.0) | .001 |
| Exercise, none/1–2/3 times/week, n (%) | 2017/654/240 (71.6/19.2/8.8) | 253/64/23 (72.5/18.6/8.9) | .001 |
| Metabolic syndrome, n (%) | 1130 (4.3) | 1168 (37.5) | .001 |
| HbA1c, %            | 5.5 ± 0.3                     | 5.7 ± 0.4                         | .001 |
| Fasting glucose, mg/dl | 80.0 ± 7.5                   | 81.8 ± 10.2                       | .001 |
| Postload 2-h glucose, mg/dl | 108.0 ± 27.9         | 102.8 ± 27.9                      | .001 |
| Fasting insulin, \( \mu \text{U/mL} \) | 6.7 ± 4.0                        | 6.8 ± 5.1                         | .001 |
| Postload 2-h insulin, \( \mu \text{U/mL} \) | 124.1 ± 22.4, 4 | 129.9 ± 29.9                      | .001 |
| HOMA-IR              | 1.35 ± 0.83                   | 1.64 ± 1.07                       | .001 |
| Total cholesterol, mg/dl | 118.3 ± 32.8                 | 127.8 ± 43.3                      | .001 |
| Triglycerides, mg/dl | 1124.3 ± 67.7                 | 1169.9 ± 101.7                    | .001 |
| LDL cholesterol, mg/dl | 74.7 ± 10.4                    | 74.0 ± 10.2                       | .001 |

BMI = body mass index, DBP = diastolic blood pressure, HbA1c = glycated hemoglobin, HDL = high-density lipoprotein, HOMA-IR = homeostasis model assessment of insulin resistance, LDL = low-density lipoprotein, IGI = insulinogenic index, KDS = Korean diabetes score, SBP = systolic blood pressure.

\( P \) values were calculated from analysis of variance test for continuous variables and chi-squared tests for categorical variables, respectively.

\( ^{*} P < .05; ^{1} P < .01; ^{2} P < .001 \) between nondiabetes and incident diabetes among individuals with KDS < 5.

\( ^{*} P < .05; ^{1} P < .01; ^{2} P < .001 \) between nondiabetes and incident diabetes among individuals with KDS ≥ 5.

\( ^{2} P < .001 \) between individuals with non-diabetes and KDS ≥ 5 versus individuals with incident diabetes and KDS < 5.
Further, we investigated the performance of KDS in addition to different risk factors for the prediction of incident diabetes over 10 years by ROC analyses. As shown in Table 3, the AUC of the univariate logistic model of KDS score was 0.641 (95% CI, 0.627–0.656) and it increased to 0.780 (95% CI, 0.767–0.793) in the multivariate comprehensive model of KDS, fasting glucose, HbA1c, and postload 2-hour glucose. The multivariate combination model of KDS in addition to fasting glucose, HbA1c, postload 2-hour glucose, and triglyceride showed the highest AUC of 0.782 (95% CI 0.769–0.795). The performance of other risk scores including US screening score,[27] Thai score,[28] and Rotterdam model,[29] revealed AUCs ranged from 0.579 to 0.643 (Supplementary table 1, http://links.lww.com/MD/B726).

To investigate whether KDS score reflects components of insulin resistance or beta-cell function, we analyzed AUCs of risk models of HOMA-IR or IGI for predicting KDS ≥ 5 (Supplementary table 2, http://links.lww.com/MD/B726). An AUC of 0.613 (95% CI 0.601–0.625) with HOMA-IR index was higher than IGI (AUC, 0.476; 95% CI, 0.462–0.490), indicating KDS might represent an insulin resistance component more than beta-cell function. In subgroup analyses of age, individuals younger than 50 years revealed markedly higher values of AUCs than those older than 50 years for predicting incident diabetes in all of these models.

### Table 2: Association of KDS with the incidence of diabetes in the Cox proportional hazards models.

| HR 95% CI    | P    |
|--------------|------|
| KDS, per 1 point | 1.13 | 1.09–1.18 | <.001 |
| Sex (0 = male, 1 = female) | 0.85 | 0.76–0.96 | .010 |
| BMI, per 1 kg/m² | 1.00 | 0.98–1.02 | .804 |
| Exercise, none/wk | Referent |
| Exercise, 1–3 times/wk | 0.94 | 0.82–1.09 | .413 |
| Exercise, ≥4 times/wk | 1.00 | 0.82–1.22 | .985 |
| HbA1c, per 1% | 2.57 | 2.25–2.94 | <.001 |
| Fasting glucose, per 10 mg/dL | 1.29 | 1.21–1.38 | <.001 |
| Postload 2-h glucose, per 10 mg/dL | 1.20 | 1.17–1.22 | <.001 |
| Total cholesterol, per 10 mg/dL | 0.99 | 0.97–1.01 | .139 |
| Triglyceride, per 10 mg/dL | 1.01 | 1.01–1.02 | <.001 |
| HDL cholesterol, per 5 mg/dL | 0.97 | 0.94–1.01 | .107 |
| IGI | 0.93 | 0.89–0.97 | .001 |
| HOMA-IR index | 1.01 | 0.91–1.11 | .916 |

Bold font indicates the HR is significantly elevated. CI = confidence interval; HDL = high density lipoprotein; HOMA-IR = homeostasis model assessment of insulin resistance; HR = hazard ratio; IGI = insulinogenic index; KDS = Korean Diabetes Score.

*Variables are log-transformed.

#### 3.3. Predictive parameters for incident diabetes according to KDS

We further evaluated significant clinical and laboratory parameters to predict the likelihood of developing diabetes during 10 years of follow-up in participants having KDS < 5 at baseline (Table 4). Cox proportional hazards analysis showed that systolic blood pressure (SBP), family history of diabetes, HbA1c, fasting glucose, postload 2-hour glucose, triglyceride, and IGI were independently associated with incident diabetes in subjects with KDS < 5 at baseline. In addition, a family history of diabetes, current smoking, increased SBP, HbA1c, fasting glucose, postload 2-hour glucose, triglyceride, and decreased IGI were significant predictors of an increased likelihood of incident diabetes in subjects having baseline KDS ≥ 5. Collectively, common independent parameters for predicting diabetes were the presence of family history of diabetes, increased SBP, HbA1c, fasting glucose, postload 2-hour glucose, and decrease in IGI, which indicates decline in beta-cell function.

#### 4. Discussion

In the present study, we investigated and validated the KDS to predict diabetes in a 10-year longitudinal data. We confirmed that subjects with a baseline KDS ≥ 5 were significantly associated with a high incidence of diabetes, and that the KDS risk model becomes more potent in combination with various laboratory parameters. In particular, there is an increased ability to predict
diabetes using the KDS in participants younger than 50 years compared to those over 50 years. In addition, low IGI, representing impaired beta-cell function, was an independent determinant of incident diabetes in low-risk individuals with baseline KDS < 5.

Every 1-point increase in the KDS revealed a significantly increased risk of developing diabetes. Moreover, levels of HbA1c, fasting glucose, postload 2-hour glucose, and triglyceride were also shown as strong predictors for diabetes in this study, as previously suggested. Decreased beta-cell function was shown to be the major determinant for the development of type 2 diabetes, which limits compensation in response to minor progressive insulin resistance in Asians; otherwise, a compensatory increase of beta-cell function was revealed with deeply declined insulin sensitivity in White people. Consistent with this, compared to HOMA-IR index (AUC, 0.579; 95% CI, 0.562–0.595), IGI presented a higher AUC of 0.604 (95% CI, 0.587–0.620) in predicting diabetes (Table 3).

Furthermore, we evaluated independent factors to predict incident diabetes in people with baseline KDS ≥ 5 who ultimately developed diabetes using the Cox regression model, and also found that low IGI was an independent predictor. In particular, current smoking had a significant adjusted HR of 1.49 (95% CI, 1.19–1.87) for the risk of diabetes in participant having baseline KDS ≥ 5; therefore, as a modifiable risk factor, smoking cessation should be emphasized to people with baseline KDS score ≥ 5.

In terms of the AUC, the KDS demonstrated a modest level of accuracy in predicting diabetes (0.641; 95% CI, 0.627–0.656) with a sensitivity of 61% and a specificity of 61%. Other risk scores including Thai score, Rotterdam model, and US screening score had AUCs ranged from 0.579 to 0.643 with the sensitivities from 63% to 77% and the relatively low specificities from 36% to 57%. In the previous study regarding performance of the KDS risk model using cross-sectional data, the KDS had an AUC of 0.730 with a cut-off point of KDS ≥ 5. Also, a recent study reported an AUC of 0.696 (95% CI, 0.653–0.737) among 3029 individuals with a mean follow-up period of 6.2 years, in which the definition of diabetes was different (e.g., fasting glucose ≥ 126 mg/dL or HbA1c ≥ 6.5%) from the present study. In the present study, the risk prediction model for diabetes performed better up to an AUC of 0.782 (95% CI, 0.769–0.795) with a sensitivity of 69% and a specificity of 74% in the comprehensive risk model of KDS combined with laboratory parameters, including concentrations of fasting glucose, HbA1c, postload 2-hour glucose, and triglyceride. Our 10-year longitudinal results revealed lower AUCs compared to a previous study with cross-sectional data or a shorter follow-up period. The tendency toward lower AUC values in longitudinal data compared to the AUCs in cross-sectional data was also seen in the previous study. This might be affected by an insufficiency of KDS for representing beta-cell function rather than insulin sensitivity, because impaired beta-cell function is more dependent than insulin resistance in the predisposition to diabetes in Asian people.

Furthermore, because KDS is an effective primary screening tool for predicting nonalcoholic fatty liver disease or nonalcoholic steatohepatitis, which is strongly associated with insulin resistance, this also revealed that the KDS strongly reflects insulin sensitivity. In line with this, in subgroup analyses, all of the risk prediction models demonstrated higher accuracy in predicting diabetes in people younger than 50 years, whose beta-cell function is more preserved in general (IGI, 15.7 vs 13.3; HOMA-IR, 1.55 vs 1.57; P = .014; HOMA-IR, 1.55 vs 1.57; P = .016; age ≤ 50 years old vs age > 50 years old) compared to those older than 50 years.

The present study has several distinguishable strengths. It is the first study to investigate the ability of the KDS to predict incident diabetes in a large population over 10 years of follow-up. Therefore, we could analyze the real-world longitudinal results. Further, we evaluated numerous risk prediction models with laboratory parameters based on KDS to compare the likelihood...
Table 4
Cox regression analysis of the variables associated with the development of diabetes among subjects according to KDS < 5 and KDS ≥ 5.

| KDS < 5 (total, N = 3388; incident diabetes, N = 349) | KDS ≥ 5 (total, N = 5347; incident diabetes, N = 1164) |
|---|---|
| **HR** | **95% CI** | **P** | **HR** | **95% CI** | **P** |
| **Age, y** | 1.05 | 0.99–1.02 | 0.472 | 1.00 | 0.99–1.01 | 0.976 |
| Sex (0 = male, 1 = female) | 1.05 | 0.97–1.12 | 0.291 | 1.01 | 0.96–1.06 | 0.474 |
| BMI, per 1 kg/m² | 1.01 | 0.98–1.04 | 0.676 | 1.01 | 0.98–1.04 | 0.722 |
| SBP, per 1 mm Hg | 1.08 | 1.04–1.22 | <0.001 | 1.05 | 1.04–1.18 | <0.001 |
| **Family history of diabetes** | 1.82 | 1.29–2.57 | <0.001 | 1.24 | 1.03–1.50 | 0.023 |
| Smoking, never | Referent | Referent | Referent | Referent | Referent | Referent |
| Smoking, past | 1.39 | 0.96–2.05 | 0.092 | 1.21 | 0.88–1.66 | 0.132 |
| Smoking, current | 1.41 | 1.00–2.15 | 0.116 | 1.49 | 1.19–1.87 | 0.001 |
| Exercise, none/wk | Referent | Referent | Referent | Referent | Referent | Referent |
| Exercise, 1–3 times/wk | 0.85 | 0.63–1.15 | 0.290 | 0.98 | 0.83–1.15 | 0.813 |
| Exercise, ≥ 4 times/wk | 1.17 | 0.77–1.78 | 0.469 | 1.01 | 0.83–1.28 | 0.910 |
| **HbA1c, per 1%** | 2.66 | 1.92–3.67 | <0.001 | 2.58 | 2.22–3.01 | <0.001 |
| Fasting glucose, per 10 mg/dL | 1.33 | 1.14–1.54 | <0.001 | 1.28 | 1.18–1.39 | <0.001 |
| Postload 2-hour glucose, per 10 mg/dL | 1.23 | 1.16–1.29 | <0.001 | 1.18 | 1.16–1.21 | <0.001 |
| Total cholesterol, per 10 mg/dL | 0.99 | 0.96–1.04 | 0.774 | 0.98 | 0.96–1.00 | 0.386 |
| Triglyceride, per 10 mg/dL | 1.02 | 1.01–1.03 | 0.200 | 1.01 | 1.01–1.03 | <0.001 |
| HDL cholesterol, per 10 mg/dL | 0.94 | 0.87–1.01 | 0.078 | 0.98 | 0.94–1.02 | 0.270 |
| **IGI** | 0.88 | 0.81–0.96 | <0.057 | 0.94 | 0.89–0.99 | 0.023 |
| **HOME-IR index** | 1.02 | 0.83–1.27 | 0.843 | 0.99 | 0.89–1.11 | 0.896 |

Bold font indicates the HR is significantly elevated. CI = confidence interval, HDL = high density lipoprotein, HOME-IR = homeostasis model assessment of insulin resistance, HR = hazard ratio, IGI = insulinogenic index, KDS = Korean Diabetes Score, SBP = systolic blood pressure.

Variables are log-transformed.

In conclusion, we investigated and validated the KDS in a well-designed cohort over 10 years and found that additional KDS combined with various laboratory parameters may be more effective for predicting diabetes than KDS alone. Furthermore, beta-cell function is a crucial independent determinant for developing diabetes in Koreans, which also may be considered for diabetes risk prediction when estimated using KDS.

Acknowledgments

Data in this study were from the Korean Genome and Epidemiology Study (KoGES; 4851–302), National Research Institute of Health, Centers for Disease Control and Prevention, Ministry for Health and Welfare, Republic of Korea.

References

[1] Zimmet PZ, Magliano DJ, Herman WH, et al. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2014;2:56–64.
[2] Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract 2014;103:137–49.
[3] Menke A, Casagrande S, Geiss L, et al. Prevalence of and trends in diabetes among adults in the United States, 1980–2012. JAMA 2013;314:1021–9.
[4] Chan JC, Malik V, Jia W, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009;301:2129–40.
[5] Ramachandran A, Ma RC, Snehalatha C. Diabetes in Asia. Lancet 2010;375:408–18.
[6] Stratton IM, Adler AI, Neil HA, et al. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–12.
[7] da Rocha Fernandes J, Ogurtsova K, Linnenkamp U, et al. IDF Diabetes Atlas estimates of 2014 global health expenditures on diabetes. Diabetes Res Clin Pract 2016;117:48–54.
[8] Economic costs of diabetes in the U.S. in 2012. Diabetes Care 2013;36:1033–46.
[9] Glümer C, Carstensen B, Sandbaek A, et al. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care 2004;27:727–33.
[10] Lin JW, Chang YC, Li HY, et al. Cross-sectional validation of diabetes risk scores for predicting diabetes, metabolic syndrome, and chronic kidney disease in Taiwanese. Diabetes Care 2009;32:2294–6.

[11] Franciosi M, De Berardis G, Rossi MC, et al. Use of the diabetes risk score for opportunistic screening of undiagnosed diabetes and impaired glucose tolerance: the IGLOO (Impaired Glucose Tolerance and Long-Term Outcomes Observational) study. Diabetes Care 2005;28:1187–94.

[12] Gao WG, Dong YH, Pang ZC, et al. A simple Chinese risk score for undiagnosed diabetes. Diabet Med 2010;27:274–81.

[13] Yabe D, Seino Y. Type 2 diabetes via beta-cell dysfunction in East Asian people. Lancet Diabetes Endocrinol 2016;4:2–3.

[14] Nanditha A, Ma RC, Ramachandran A, et al. Diabetes in Asia and the pacific: implications for the global epidemic. Diabetes Care 2016;39:472–85.

[15] Lee YH, Bang H, Kim HC, et al. A simple screening score for diabetes for the Korean population: development, validation, and comparison with other scores. Diabetes Care 2012;35:1723–30.

[16] Han BG, the KoGES group. Cohort Profile: The Kim Y, Korean Genome and Epidemiology study (KoGES) consortium. Int J Epidemiol 2016;1–9.

[17] International Association for the Study of Obesity. The Asia-Pacific perspective: redefining obesity and its treatment. 2000.

[18] Chang SA, Kim HS, Yoon KH, et al. Body mass index is the most important determining factor for the degree of insulin resistance in non-obese type 2 diabetic patients in Korea. Metabolism 2004;53:142–6.

[19] Oh SW. Obesity and metabolic syndrome in Korea. Diabetes Metab J 2011;35:561–6.

[20] Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27 (Suppl 1):S5–10.

[21] Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412–9.

[22] Selzter HS, Allen EW, Herron AL Jr, et al. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. J Clin Invest 1967;46:323–35.

[23] Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005;112:2735–52.

[24] Lim S, Kim JH, Yoon JW, et al. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care 2010;33:1652–4.

[25] Kim G, Lee YH, Park YM, et al. Use of a diabetes self-assessment score to predict nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Medicine (Baltimore) 2015;94:e1103.

[26] DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–45.

[27] Rang H, Edwards AM, Bombac A, et al. Development and validation of a patient self-assessment score for diabetes risk. Ann Intern Med 2009;151:775–83.

[28] Aekplakorn W, Bunnag P, Woodward M, et al. A risk score for identifying undiagnosed diabetes in the Thai population. Diabetes Care 2006;29:1872–7.

[29] Baan CA, Ruige JB, Stolk RP, et al. Performance of a predictive model to identify undiagnosed diabetes in a health care setting. Diabetes Care 1999;22:213–9.

[30] Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care 2007;30:228–33.

[31] Soderberg S, Zimmet P, Tuomilehto J, et al. High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. J Intern Med 2004;256:37–47.

[32] Bennett CM, Guo M, Dharmage SC. HbA(1c) as a screening tool for detection of type 2 diabetes: a systematic review. Diabet Med 2007;24:333–43.

[33] Tirosh A, Shai I, Bitzur R, et al. Changes in triglyceride levels over time and risk of type 2 diabetes in young men. Diabetes Care 2008;31:2032–7.

[34] Marimoto A, Tatsumi Y, Deura K, et al. Impact of impaired insulin secretion and insulin resistance on the incidence of type 2 diabetes mellitus in a Japanese population: the Saku study. Diabetologia 2013;56:1671–9.

[35] Ohn JH, Kwak SH, Cho YM, et al. 10-year trajectory of beta-cell function and insulin sensitivity in the development of type 2 diabetes: a community-based prospective cohort study. Lancet Diabetes Endocrinol 2016;4:27–34.

[36] Tabak AG, Jokela M, Akbaraly TN, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II Study. Lancet 2009;373:2215–21.

[37] Ahn CH, Yoon JW, Hahn S, et al. Evaluation of non-laboratory and laboratory prediction models for current and future diabetes mellitus: a cross-sectional and retrospective cohort study. PLoS One 2016;11:e0156155.